Log In
Print this Print this

Oxtellar XR, oxcarbazepine (Epliga) (formerly SPN-804)

  Manage Alerts
Collapse Summary General Information
Company Supernus Pharmaceuticals Inc.
DescriptionOral, once-daily extended-release formulation of oxcarbazepine
Molecular Target Sodium channel
Mechanism of ActionNa channel blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationSeizures
Indication DetailsTreat refractory partial onset seizures as adjunctive therapy in patients with epilepsy
Regulatory Designation
PartnerAequus Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today